Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate

FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically administered siRNA drug candidate QPI-1002 (previously referred to as DGFi) for prevention of Delayed Graft Function (DGF) in patients undergoing deceased donor kidney transplantation. DGF represents Quark's second indication being evaluated for the systemically administered dug candidate in human clinical trials. This trial follows two currently enrolling Phase I clinical trials in acute kidney injury (AKI).

The multi-center, two-part Phase I/II clinical trial in DGF is expected to enroll up to 204 adult kidney transplant recipients. The first part of the study is a dose-escalation design to evaluate the safety and tolerability of a single intravenous injection of QPI-1002 in renal transplant patients at high risk to develop DGF. The second part of the study will evaluate safety and potential clinical activity of a selected dose of QPI-1002 in the same patient population. Patients will be enrolled in clinical sites in the United States.

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "The initiation of patient dosing with QPI-1002 is an important milestone for Quark as well as being an innovative approach to offer therapeutic benefit to adult kidney transplant patients at high risk for developing DGF. The siRNA drug candidate is based on the proprietary concept of Quark and reflects Quark's success in developing products originating from conceptually novel internal developments. These accomplishments further validate Quark's ability to advance innovative product candida
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- The American Association for Homecare (AAHomecare) is pleased ... joined the AAHomecare Corporate Partner Program. ... been actively involved in AAHomecare for much of the ... into a major global manufacturer of home medical equipment. ... increase efforts on behalf of the HME sector in ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Larry J. Merlo , President and CEO of CVS ... National Press Club in Washington, D.C. ... selling tobacco products and its leadership in driving the innovations ... changes in our health care system pose enormous challenges to ... "CVS Health has a truly unique combination of business assets ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
(Date:9/21/2014)... of the leading online stores of real and synthetic hair ... human hair lace wigs inspired by 6 famous celebrities. It’s ... latest celebrity hairstyles are. , For people who ... to choose from: a style of yaki straight lace wig, ... ombre red lace wig. People can go to the product ...
(Date:9/21/2014)... United-Kingdom (PRWEB) September 22, 2014 PhUSE ... Sweeney and Dr. Lilliam Rosario as keynote speakers for ... Following keynotes from Dr. Ben Goldacre in 2013 ... Professor Lord Winston in 2011 , PhUSE again presents ... who are passionate about advancement of clinical information. , ...
(Date:9/21/2014)... September 21, 2014 Waldorf Risk ... Management Portal designed for Diocesan risks. The portal ... to support effective risk management and loss control ... live coinciding with Waldorf’s exhibition at the Diocesan ... These applications were developed in collaboration with three ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... Cheap Hosting USA, one of the leading review websites, ... the best Reseller hosting suppliers in 2014. “It is ... these companies have outperformed their competitors on hosting features, ... the best web hosting at affordable rates,” the site’s ... reseller hosting is a very popular way for webmasters ...
Breaking Medicine News(10 mins):Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2
... at the University of Cincinnati (UC) suggests that ... process that can provide cells with nutrients from ... can protect tumor cells from chemotherapy, allowing them ... a hidden, dormant, metastatic state. In this ...
... NY It should be possible to significantly improve ... drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), ... cells with their immediate surroundings, called the tumor microenvironment. ... Cancer Cell , CSHL Assistant Professor Mikala Egeblad ...
... , MONDAY, April 16 (HealthDay News) -- The ... surgery increased drastically in 2011, according to the American ... augmentation procedures was greater than breast augmentation, Botox injections ... chin augmentation may include increased use of video-chat technology, ...
... Indiana University and the Regenstrief Institute have developed an ... the specific health needs of each patient in the ... new study, "Automated Primary Care Screening in Pediatric Waiting ... found that by personalizing and automating the patient ...
... the place where an estimated 30 percent of Americans die, there ... job at managing end of life care. A new study ... is starting a discussion over the need to create end of ... nursing homes with incentive to improve care. "Nursing homes are ...
... (April 16, 2012) Cancer is much more likely in the ... to fight the disease and the often-toxic side effects of treatment. ... Research Center at The University of Texas Health Science Center at ... work only in younger patients can be used to help the ...
Cached Medicine News:Health News:Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer 2Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 2Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 3Health News:Chin Implant Surgeries On the Rise in U.S. 2Health News:IU, Regenstrief automated system aims to improve child health 2Health News:IU, Regenstrief automated system aims to improve child health 3Health News:Study recommends ways to evaluate end-of-life care in nursing homes 2Health News:Study recommends ways to evaluate end-of-life care in nursing homes 3Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 2Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 3
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... is a high performance assay for the ... B with a simple, easy-to-use test that ... minutes. Assay advantages include superior performance with ... to 14-day viral culture enables you to ...
... The CHLAYMDIA OIA test delivers 100% ... results in 19 minutes. With ... not returning for follow-up, this assay ... which can contribute to detection and ...
... therapy and nerve block procedures, Cadwells ... has a precisely machined Trocar (beveled) ... attached 61-cm (24-in) lead wire. Needle ... patient use only. A starter kit ...
Medicine Products: